ALLMedicine™ Multiple Sclerosis Center

May 15th, 2021 - Quality of life in multiple sclerosis (MS) reflects complex relationships between symptoms (fatigue, spasticity pain, and bladder or vision dysfunction), disability, health perceptions, and self-efficacy. In this cross-sectional study, a self-repo...

May 15th, 2021 - Multiple Sclerosis (MS) is caused by a still unknown interplay between genetic and environmental factors. Epigenetics, including DNA methylation, represents a model for environmental factors to influence MS risk. Twenty-six affected and 26 unaffec...

May 14th, 2021 - To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed. A number of retrospective observa...

May 14th, 2021 - Multiple sclerosis (MS) is associated with deficits in social cognition, the process underlying social interaction and cognitive function. However, the relationships between executive impairment and social cognition remain unclear in MS. Previous ...

May 14th, 2021 - N-acylethanolamine acid amidase (NAAA) is an N-terminal cysteine hydrolase that stops the physiological actions of palmitoylethanolamide (PEA), an endogenous lipid messenger that activates the transcription factor, peroxisome proliferator-activate...

Jul 17th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...

May 13th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|

Apr 24th, 2020 - To examine the immediate and sustained effects of interventions for changing physical activity behavior in people with multiple sclerosis (MS), and explore factors that might moderate intervention effects on physical activity behavior (e.g., inter...

Apr 16th, 2020 - We propose a possible approach for the remote monitoring of infection risk in people with multiple sclerosis, especially those on immunosuppressant drugs, during COVID-19 pandemic. We developed a digital triage tool to be sent to patients to quick...

Feb 27th, 2020 - Over more than 35 years, advances in magnetic resonance imaging (MRI) techniques and analysis have fundamentally impacted both diagnostic criteria and treatment algorithms for multiple sclerosis (MS), a potentially disabling neurologic condition t...

May 15th, 2021 - Quality of life in multiple sclerosis (MS) reflects complex relationships between symptoms (fatigue, spasticity pain, and bladder or vision dysfunction), disability, health perceptions, and self-efficacy. In this cross-sectional study, a self-repo...

May 15th, 2021 - Multiple Sclerosis (MS) is caused by a still unknown interplay between genetic and environmental factors. Epigenetics, including DNA methylation, represents a model for environmental factors to influence MS risk. Twenty-six affected and 26 unaffec...

May 14th, 2021 - To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed. A number of retrospective observa...

May 14th, 2021 - Multiple sclerosis (MS) is associated with deficits in social cognition, the process underlying social interaction and cognitive function. However, the relationships between executive impairment and social cognition remain unclear in MS. Previous ...

May 14th, 2021 - N-acylethanolamine acid amidase (NAAA) is an N-terminal cysteine hydrolase that stops the physiological actions of palmitoylethanolamide (PEA), an endogenous lipid messenger that activates the transcription factor, peroxisome proliferator-activate...

May 12th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Dr Ilya Kister Antibody response is reduced in patients with multiple sclerosis (MS) who take a specific disease-modifying therapy (DMT) while inf...

Apr 28th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. When it comes to SARS-CoV-2 infection among patients with multiple sclerosis (MS), disease-modifying therapies (DMTs) seem to have varying effects...

Apr 25th, 2021 - The investigational drug tolebrutinib effectively reduces brain lesions in patients with highly active relapsing-remitting multiple sclerosis (RRMS), new research suggests. After 12 weeks of treatment, MRI revealed the drug, a Bruton's tyrosine ki...

Apr 18th, 2021 - For women with multiple sclerosis (MS), results of MRI performed during the year before they become pregnant appear to accurately predict early relapse after childbirth, new research shows. Investigators found that women for whom there was evidenc...

Apr 16th, 2021 - Black patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to common MS treatment compared to their White peers, new research suggests. In a study of almost 200 patients, Black participant...